Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Generation of Markerless Deletions in the Nosocomial Pathogen Clostridium difficile by Induction of DNA Double-Strand Breaks.

Theophilou ES, Vohra P, Gallagher MP, Poxton IR, Blakely GW.

Appl Environ Microbiol. 2019 Jan 23;85(3). pii: e02055-18. doi: 10.1128/AEM.02055-18. Print 2019 Feb 1.

2.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators.

N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.

3.

Equine grass sickness, but not botulism, causes autonomic and enteric neurodegeneration and increases soluble N-ethylmaleimide-sensitive factor attachment receptor protein expression within neuronal perikarya.

McGorum BC, Scholes S, Milne EM, Eaton SL, Wishart TM, Poxton IR, Moss S, Wernery U, Davey T, Harris JB, Pirie RS.

Equine Vet J. 2016 Nov;48(6):786-791. doi: 10.1111/evj.12543. Epub 2016 Jan 11.

PMID:
26640078
4.

Humoral immune response as predictor of recurrence in Clostridium difficile infection.

Bauer MP, Nibbering PH, Poxton IR, Kuijper EJ, van Dissel JT.

Clin Microbiol Infect. 2014 Dec;20(12):1323-8. doi: 10.1111/1469-0691.12769. Epub 2014 Dec 12.

5.

International Clostridium difficile animal strain collection and large diversity of animal associated strains.

Janezic S, Zidaric V, Pardon B, Indra A, Kokotovic B, Blanco JL, Seyboldt C, Diaz CR, Poxton IR, Perreten V, Drigo I, Jiraskova A, Ocepek M, Weese JS, Songer JG, Wilcox MH, Rupnik M.

BMC Microbiol. 2014 Jun 28;14:173. doi: 10.1186/1471-2180-14-173.

6.

A prospective study of community-associated Clostridium difficile infections: the role of antibiotics and co-infections.

Taori SK, Wroe A, Hardie A, Gibb AP, Poxton IR.

J Infect. 2014 Aug;69(2):134-44. doi: 10.1016/j.jinf.2014.04.002. Epub 2014 Apr 26.

PMID:
24780765
7.

In memoriam--Professor J Gerald (Gerry) Collee CBE, FRSE, MD, FRCPath, FRCPE (1929-2013).

Duerden BI, Watt B, Poxton IR.

J Med Microbiol. 2014 Apr;63(Pt 4):623-4. doi: 10.1099/jmm.0.070508-0. Epub 2014 Feb 3. No abstract available.

PMID:
24493158
8.

Comparative proteomic analysis of Clostridium difficile isolates of varying virulence.

Chilton CH, Gharbia SE, Fang M, Misra R, Poxton IR, Borriello SP, Shah HN.

J Med Microbiol. 2014 Apr;63(Pt 4):489-503. doi: 10.1099/jmm.0.070409-0. Epub 2014 Jan 20.

PMID:
24445512
9.

Clostridium difficile--special collection.

Rupnik M, Poxton IR.

J Med Microbiol. 2013 Sep;62(Pt 9):1368. doi: 10.1099/jmm.0.065425-0. No abstract available.

PMID:
23950217
10.

Clostridium difficile infections in South East Scotland: mortality and recurrence in a region without PCR ribotype 027.

Taori SK, Wroe A, Poxton IR.

J Med Microbiol. 2013 Sep;62(Pt 9):1468-77. doi: 10.1099/jmm.0.061093-0. Epub 2013 Jun 20.

PMID:
23788595
11.

The changing faces of Clostridium difficile: a personal reflection of the past 34 years.

Poxton IR.

Anaerobe. 2013 Dec;24:124-7. doi: 10.1016/j.anaerobe.2012.12.006. Epub 2013 Jan 4. Review.

PMID:
23296302
12.

Knowledge of Clostridium difficile infection among UK health-care workers: development of a knowledge assessment tool.

Brady RR, Rodrigues MA, Harrison R, Rae C, Graham C, Poxton IR, Gibb AP.

Scott Med J. 2012 Aug;57(3):124-30. doi: 10.1258/smj.2012.012015.

PMID:
22859801
13.

Induction of cytokines in a macrophage cell line by proteins of Clostridium difficile.

Vohra P, Poxton IR.

FEMS Immunol Med Microbiol. 2012 Jun;65(1):96-104. doi: 10.1111/j.1574-695X.2012.00952.x. Epub 2012 Apr 4.

14.

Efficacy of decontaminants and disinfectants against Clostridium difficile.

Vohra P, Poxton IR.

J Med Microbiol. 2011 Aug;60(Pt 8):1218-24. doi: 10.1099/jmm.0.030288-0. Epub 2011 Apr 7.

PMID:
21474613
15.

Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile.

Vohra P, Poxton IR.

Microbiology. 2011 May;157(Pt 5):1343-53. doi: 10.1099/mic.0.046243-0. Epub 2011 Feb 17.

PMID:
21330434
16.

A proposed nomenclature for cell wall proteins of Clostridium difficile.

Fagan RP, Janoir C, Collignon A, Mastrantonio P, Poxton IR, Fairweather NF.

J Med Microbiol. 2011 Aug;60(Pt 8):1225-8. doi: 10.1099/jmm.0.028472-0. Epub 2011 Jan 20.

PMID:
21252271
17.

Equine grass sickness: are we any nearer to answers on cause and prevention after a century of research?

Newton JR, Wylie CE, Proudman CJ, McGorum BC, Poxton IR.

Equine Vet J. 2010 Sep;42(6):477-81. doi: 10.1111/j.2042-3306.2010.00155.x. No abstract available.

PMID:
20716184
18.

Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.

Poxton IR.

Future Microbiol. 2010 Apr;5(4):539-48. doi: 10.2217/fmb.10.20. Review.

PMID:
20353295
19.

Changes in laboratory and clinical workload for Clostridium difficile infection from 2003 to 2007 in hospitals in Edinburgh.

Reddy S, Taori S, Poxton IR.

Clin Microbiol Infect. 2010 Apr;16(4):340-6. doi: 10.1111/j.1469-0691.2010.03141.x.

20.

A survey of the identification and susceptibility testing of anaerobes in diagnostic microbiology laboratories in Scotland, UK.

Smith AJ, Lockhart DE, Tyers A, Poxton IR.

J Antimicrob Chemother. 2010 Apr;65(4):805. doi: 10.1093/jac/dkq010. Epub 2010 Feb 7. No abstract available.

PMID:
20142266
21.

Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004.

Taori SK, Hall V, Poxton IR.

J Med Microbiol. 2010 Mar;59(Pt 3):338-44. doi: 10.1099/jmm.0.014829-0. Epub 2009 Nov 26.

PMID:
19942691
22.

Potential use of a liposome-encapsulated mixture of lipopolysaccharide core types (R1, R2, R3 and R4) of Escherichia coli in controlling colisepticaemia in chickens.

Dissanayake DR, Wijewardana TG, Gunawardena GA, Poxton IR.

J Med Microbiol. 2010 Jan;59(Pt 1):100-7. doi: 10.1099/jmm.0.014720-0.

PMID:
19797465
23.

Bacteroides fragilis signals through Toll-like receptor (TLR) 2 and not through TLR4.

Alhawi M, Stewart J, Erridge C, Patrick S, Poxton IR.

J Med Microbiol. 2009 Aug;58(Pt 8):1015-22. doi: 10.1099/jmm.0.009936-0. Epub 2009 Jun 15.

PMID:
19528164
24.

Spatio-temporal stochastic modelling of Clostridium difficile.

Starr JM, Campbell A, Renshaw E, Poxton IR, Gibson GJ.

J Hosp Infect. 2009 Jan;71(1):49-56. doi: 10.1016/j.jhin.2008.09.013. Epub 2008 Nov 17.

PMID:
19013677
25.

Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.

Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmée M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Akerlund T, Virolainen-Julkunen A, Lyytikäinen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, Monnet DL.

Euro Surveill. 2008 Jul 31;13(31). pii: 18942.

26.

Distribution of lipopolysaccharide core types among avian pathogenic Escherichia coli in relation to the major phylogenetic groups.

Dissanayake DR, Wijewardana TG, Gunawardena GA, Poxton IR.

Vet Microbiol. 2008 Dec 10;132(3-4):355-63. doi: 10.1016/j.vetmic.2008.05.024. Epub 2008 Jul 2.

PMID:
18597955
27.

Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe.

Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, Delmée M, Kuijper E, Poxton IR; European Study Group on Clostridium difficile (ESGCD).

J Med Microbiol. 2008 Jun;57(Pt 6):784-9. doi: 10.1099/jmm.0.47738-0.

PMID:
18480338
28.

Enhancement of the cytotoxic activity of Clostridium difficile toxin A by surface-associated antigens.

Sánchez-Hurtado K, Poxton IR.

J Med Microbiol. 2008 Jun;57(Pt 6):739-44. doi: 10.1099/jmm.0.47678-0.

PMID:
18480331
29.

Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls.

Sánchez-Hurtado K, Corretge M, Mutlu E, McIlhagger R, Starr JM, Poxton IR.

J Med Microbiol. 2008 Jun;57(Pt 6):717-24. doi: 10.1099/jmm.0.47713-0.

PMID:
18480328
30.

Clostridium difficile.

Poxton IR.

J Med Microbiol. 2008 Jun;57(Pt 6):683-4. doi: 10.1099/jmm.0.2008/002451-0. No abstract available.

PMID:
18480322
31.

Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe.

Kuijper EJ, Coignard B, Brazier JS, Suetens C, Drudy D, Wiuff C, Pituch H, Reichert P, Schneider F, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Barbut F, Delmée M, Wilcox M, Pearson A, Patel BC, Brown DJ, Frei R, Akerlund T, Poxton IR, Tüll P.

Euro Surveill. 2007 Jun 1;12(6):E1-2.

PMID:
17991399
32.

Preliminary study of mucosal IgA in the equine small intestine: specific IgA in cases of acute grass sickness and controls.

Nunn FG, Pirie RS, McGorum B, Wernery U, Poxton IR.

Equine Vet J. 2007 Sep;39(5):457-60.

PMID:
17910272
33.

Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates.

Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I; European Study Group on Clostridium difficile (ESGCD).

Clin Microbiol Infect. 2007 Nov;13(11):1048-57. Epub 2007 Sep 11.

34.

Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland.

Mutlu E, Wroe AJ, Sanchez-Hurtado K, Brazier JS, Poxton IR.

J Med Microbiol. 2007 Jul;56(Pt 7):921-9.

PMID:
17577057
36.

Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling.

Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR.

J Med Microbiol. 2007 Feb;56(Pt 2):165-71.

PMID:
17244795
37.

Comparison of IgG antibody levels to Clostridium botulinum antigens between euthanased and surviving cases of chronic grass sickness.

Nunn FG, Pirie RS, McGorum B, Wernery U, Poxton IR.

Res Vet Sci. 2007 Aug;83(1):82-4. Epub 2006 Dec 6.

PMID:
17156804
38.

"Dirty little secrets"--endotoxin contamination of recombinant proteins.

Wakelin SJ, Sabroe I, Gregory CD, Poxton IR, Forsythe JL, Garden OJ, Howie SE.

Immunol Lett. 2006 Jul 15;106(1):1-7. Epub 2006 May 11.

PMID:
16765451
39.
40.

Extensive DNA inversions in the B. fragilis genome control variable gene expression.

Cerdeño-Tárraga AM, Patrick S, Crossman LC, Blakely G, Abratt V, Lennard N, Poxton I, Duerden B, Harris B, Quail MA, Barron A, Clark L, Corton C, Doggett J, Holden MT, Larke N, Line A, Lord A, Norbertczak H, Ormond D, Price C, Rabbinowitsch E, Woodward J, Barrell B, Parkhill J.

Science. 2005 Mar 4;307(5714):1463-5.

42.

Association between Key-Gaskell syndrome and infection by Clostridium botulinum type C/D.

Nunn F, Cave TA, Knottenbelt C, Poxton IR.

Vet Rec. 2004 Jul 24;155(4):111-5.

PMID:
15328740
43.

Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and Pseudomonas aeruginosa signal via toll-like receptor 2.

Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR.

J Med Microbiol. 2004 Aug;53(Pt 8):735-40.

PMID:
15272059
44.

Equine grass sickness is associated with low antibody levels to Clostridium botulinum: a matched case-control study.

McCarthy HE, French NP, Edwards GB, Poxton IR, Kelly DF, Payne-Johnson CE, Miller K, Proudman CJ.

Equine Vet J. 2004 Mar;36(2):123-9.

PMID:
15038434
45.

A European survey of diagnostic methods and testing protocols for Clostridium difficile.

Barbut F, Delmée M, Brazier JS, Petit JC, Poxton IR, Rupnik M, Lalande V, Schneider C, Mastrantonio P, Alonso R, Kuipjer E, Tvede M; ESCMID Study Group on Clostridium difficile (ESGCD).

Clin Microbiol Infect. 2003 Oct;9(10):989-96.

46.

Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium difficile.

Drummond LJ, Smith DG, Poxton IR.

J Med Microbiol. 2003 Dec;52(Pt 12):1033-8.

PMID:
14614060
47.

Risk factors for Clostridium difficile colonisation and toxin production.

Starr JM, Martin H, McCoubrey J, Gibson G, Poxton IR.

Age Ageing. 2003 Nov;32(6):657-60.

PMID:
14600008
48.

Clostridium difficile in a geriatric unit: a prospective epidemiological study employing a novel S-layer typing method.

McCoubrey J, Starr J, Martin H, Poxton IR.

J Med Microbiol. 2003 Jul;52(Pt 7):573-8.

PMID:
12808079
49.
50.

Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period.

Drummond LJ, McCoubrey J, Smith DG, Starr JM, Poxton IR.

J Med Microbiol. 2003 Mar;52(Pt 3):259-63.

PMID:
12621092

Supplemental Content

Loading ...
Support Center